Scholarlink

<p>Dual inhibition by a single small molecule has emerged as a promising paradigm in anticancer therapy. Carbonic anhydrase isoforms IX/XII (CA IX/XII) and vascular endothelial growth factor (VEGF) are hypoxia-responsive enzymes that drive tumorigenesis and progression in hypoxic tumors through distinct mechanisms. In this study, we rationally designed and synthesized two series of 2-thioquinazolin-4-one-tethered benzenesulfonamides <b>7a-e</b>, <b>10a-e</b> as novel CA IX/XII and VEGFR-2 inhibitors. Lead compounds <b>10c</b> and <b>10e</b> exhibited potent multitarget inhibition, with IC<sub>50</sub> values of 0.145 and 0.069 μM (VEGFR-2), 0.168 and 0.077 μM (CA IX), 0.154 and 0.205 μM (CA XII), which were comparable to those of sorafenib and acetazolamide standards. These agents demonstrated broad-spectrum cytotoxicity against HeLa, HepG2, HCT-116, and MCF-7 cell lines (IC<sub>50</sub> = 11.57–21.43 μM for <b>10c</b>; 7.81–19.50 μM for <b>10e</b>). Mechanistic studies confirmed the induction of G2/M arrest by <b>10e</b>, triggering 47.25% apoptosis <i>via</i> a sevenfold Bax/Bcl-2 upregulation and 4- to 5.7-fold caspase-3 and 9 activations, consistent with intrinsic pathway engagement. Molecular docking and dynamics simulations elucidated favorable multitarget binding conformations, thereby validating the hybrid design strategy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Quinazoline-sulfonamide hybrids as multitarget anticancer agents: inhibition of carbonic anhydrase IX/XII isoforms and VEGFR-2 with in vitro and in silico validation

  • 期刊论文

  • 发表日期：

    2026年4月19日

查看全文
  • Mohamed A. Zeidan,
  • Mohammad M. Al-Sanea,
  • Mohamed R. Elnagar,
  • Mohamed M. Tawfik,
  • Hamed W. El-Shafey,
  • Samar S. Tawfik,
  • Simone Brogi,
  • Abdelrahman Hamdi

摘要

Dual inhibition by a single small molecule has emerged as a promising paradigm in anticancer therapy. Carbonic anhydrase isoforms IX/XII (CA IX/XII) and vascular endothelial growth factor (VEGF) are hypoxia-responsive enzymes that drive tumorigenesis and progression in hypoxic tumors through distinct mechanisms. In this study, we rationally designed and synthesized two series of 2-thioquinazolin-4-one-tethered benzenesulfonamides 7a-e, 10a-e as novel CA IX/XII and VEGFR-2 inhibitors. Lead compounds 10c and 10e exhibited potent multitarget inhibition, with IC50 values of 0.145 and 0.069 μM (VEGFR-2), 0.168 and 0.077 μM (CA IX), 0.154 and 0.205 μM (CA XII), which were comparable to those of sorafenib and acetazolamide standards. These agents demonstrated broad-spectrum cytotoxicity against HeLa, HepG2, HCT-116, and MCF-7 cell lines (IC50 = 11.57–21.43 μM for 10c; 7.81–19.50 μM for 10e). Mechanistic studies confirmed the induction of G2/M arrest by 10e, triggering 47.25% apoptosis via a sevenfold Bax/Bcl-2 upregulation and 4- to 5.7-fold caspase-3 and 9 activations, consistent with intrinsic pathway engagement. Molecular docking and dynamics simulations elucidated favorable multitarget binding conformations, thereby validating the hybrid design strategy.